[Eicosanoids, myocardial ischemia and sudden death].
An activation of the arachidonic acid cascade has long been reported in coronary artery diseases. However, no clear-cut connection has been demonstrated between this activation and the clinical manifestations of myocardial ischemia. Controlled trials with the available cyclooxygenase inhibitory drugs support the view that these agents might be useful in subgroups of patients. However, these are not known. The peculiar pharmacologic properties of prostacyclin and PGE1 have been documented to improve experimental and clinical acute myocardial ischemia. Further efforts are needed to elucidate the usefulness of some PGs in the management of patients with ischemic heart disease and their contributory role to the disease.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors; D003645:Death, Sudden / Q000517:prevention & control*; D004176:Dipyridamole / Q000008:administration & dosage; D004285:Dogs; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000008:administration & dosage
D016861:Cyclooxygenase Inhibitors; D004176:Dipyridamole; D011464:Epoprostenol; D001241:Aspirin; D013442:Sulfinpyrazone
Icosanoïdes, ischémie myocardique et mort subite.